The reimbursement framework

China's basic medical insurance covers over 1.35 billion people — the world's largest single-payer drug market. Whether a drug enters the National Reimbursement Drug List (NRDL) determines access to the mainstream market; drugs left out are confined to self-pay pharmacies and high-end private hospitals.

  • National Healthcare Security Administration (NHSA): formed in 2018, combining drug pricing, catalogue management, centralised procurement and fund supervision — the "ultimate payer" for pharma in China.
  • Provincial bureaus: implement the catalogue and organise local procurement.

NRDL entry

Dynamic adjustment

Since 2018, the NRDL has shifted from infrequent updates to annual adjustment: enterprise application → formal review → expert review → negotiation/bidding → publication.

Negotiation vs. bidding

MechanismApplies toPricing
Negotiated entryHigh-clinical-value, higher-priced patent-exclusive drugs (mainly innovative drugs)Price negotiation between company and NHSA to agree a reimbursement standard; valid for two years, then renegotiated.
Bidding entryNon-exclusive drugs with multiple manufacturers (post-patent originals and generics)Competitive bidding; the lowest bidder secures the reimbursement standard.

The commercial reality of "reimbursement negotiation": NHSA uses the purchasing power of 1.35 billion insured people to demand steep price cuts in exchange for catalogue access. "Volume for price" is the core logic — accepting cuts of typically 30–60% (sometimes over 80%) in return for access to public hospitals nationwide.

Our NRDL services

  • Negotiation strategy: price bands and floors based on clinical value, competition, remaining patent life and international reference pricing.
  • Pharmacoeconomic support: evaluation reports and budget-impact analyses.
  • Price-commitment clause review: ensuring the signed agreement is legally precise and enforceable.
  • Renewal strategy: whether to hold, cut further, or exit the catalogue at the two-year renewal.

Volume-based procurement (VBP)

Legal nature

VBP is government-led bulk procurement, organised by NHSA with provinces or provincial alliances as the buyers. It sits between public and commercial procurement — administratively driven, yet the resulting supply contracts are civil in nature.

Core bid-compliance requirements

  • Quality and supply commitments: the winner must be able to supply stably at the bid price; "no profit" is not a valid excuse to stop.
  • Price constraints: bids may not exceed the lowest listed price on provincial platforms; bid-rigging and price-fixing are prohibited.
  • Subcontracting restrictions: the winning product's contract manufacturer may not further subcontract.

Post-award risks

  • Supply interruption: failing to supply leads to the "violation list", loss of VBP eligibility for all products for a period, and civil damages to hospitals.
  • Quality risk: cutting costs by lowering quality standards triggers GMP enforcement and product liability.
  • Selective supply: supplying only major cities and skipping remote areas is a breach.

Pricing and antitrust

Although most government drug pricing was liberalised in 2015, pricing remains constrained on several fronts:

  • Horizontal agreements: price-fixing, market-sharing or output-restriction among competitors violates the Anti-Monopoly Law (Art. 17); API monopolies are a recent enforcement focus.
  • Abuse of dominance: unfair high pricing, exclusive dealing or tying by dominant firms (e.g. sole API suppliers) violates Art. 22; "ten-fold" API price hikes have drawn heavy fines.
  • Price fraud: unclear labelling or false discounts are constrained by the Price Law and Consumer Protection Law.

Healthcare-security-fund supervision — a new risk area

The 2021 Regulations on Supervision of Healthcare Security Fund Use extend fund supervision to drug companies. Companies defrauding the fund through inflated costs, drug substitution or fictitious purchases face:

  • Return of the defrauded funds
  • Fines of 2–5× the amount defrauded
  • Credit sanctions — "serious" and "especially serious" ratings suspend or cancel products from procurement platforms
  • Referral for criminal prosecution (fraud) in serious cases